Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499471 | 1.00 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL22394813 | 1.00 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL29875534 | 1.00 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL22394821 | 1.00 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL30714433 | 1.00 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL642009 | 0.85 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL642008 | 0.85 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL5526283 | 0.85 | KDM1A (0.45) | KDM1ARECQLKCNQ3KCNQ2KCNE1 | |
| SCHEMBL640674 | 0.82 | CES2 (0.50) | KDM1ARECQLLMNAGFERKMT2A | |
| SCHEMBL14829243 | 0.82 | NPFFR2 (0.52) | KDM1ARECQLGRIN2BLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704096-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4291183-B1 | OXADIAZOLYL DIHYDROPYRANO[2,3-B]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250179084-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117479934-A | HIPK2 inhibitors for the treatment of renal fibrosis | 西奈山伊坎医学院 | 2024-01-30 | — | — | CN | disclosed |
| CN-112204012-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-4291183-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-B]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022173795-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3704096-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-1581213-A4 | 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2008-11-19 | — | — | EP | disclosed |
| CN-100364531-C | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-7317029-B2 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20070112003-A1 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof | CYTOVIA, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-7144876-B2 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| CN-1756547-A | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC | 2006-04-05 | — | — | CN | disclosed |
| EP-1581213-A1 | 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058253-A1 | 3,5-DISUBSTITUTED-[1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP3, CASP2 | KDM1A 2094/4885RECQL 2071/4885KCNQ3 4759/4885 |
| US-20070112003-A1 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof | CASP1, CASP3, CASP2 | KDM1A 1823/4885RECQL 2682/4885KCNQ3 4749/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KDM1A 4571/4885RECQL 2031/4885KCNQ3 4585/4885 |
| US-20250179084-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | HIPK2, HIPK3, HIPK1 | KDM1A 1334/4885RECQL 2909/4885KCNQ3 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.